Invesco Ltd. Has $445.57 Million Stock Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Invesco Ltd. lessened its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,846,881 shares of the medical device company’s stock after selling 147,164 shares during the quarter. Invesco Ltd. owned approximately 2.43% of Cooper Companies worth $445,574,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank bought a new stake in Cooper Companies during the 4th quarter worth approximately $217,906,000. FMR LLC lifted its position in shares of Cooper Companies by 97.6% during the fourth quarter. FMR LLC now owns 2,218,112 shares of the medical device company’s stock valued at $203,911,000 after purchasing an additional 1,095,805 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Cooper Companies during the 4th quarter worth $64,826,000. Victory Capital Management Inc. raised its holdings in shares of Cooper Companies by 14.6% in the 4th quarter. Victory Capital Management Inc. now owns 4,525,018 shares of the medical device company’s stock worth $415,985,000 after purchasing an additional 574,899 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in Cooper Companies by 13.2% during the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock worth $543,979,000 after purchasing an additional 573,908 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have weighed in on COO shares. JPMorgan Chase & Co. lowered their price target on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Friday, March 7th. Robert W. Baird lowered their price objective on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research report on Friday, March 7th. Finally, BNP Paribas upgraded Cooper Companies to a “hold” rating in a research report on Thursday, March 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.25.

Cooper Companies Stock Performance

Shares of COO stock opened at $71.50 on Wednesday. The company has a market cap of $14.30 billion, a P/E ratio of 36.67, a PEG ratio of 2.25 and a beta of 1.01. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The Cooper Companies, Inc. has a 12 month low of $70.45 and a 12 month high of $112.38. The firm has a fifty day moving average price of $86.17 and a 200 day moving average price of $95.43.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The business had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Sell-side analysts predict that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.